MAP2K7 and melanoma: Of note, while the effectiveness of combined MEK and CDK4/6 inhibitors has been demonstrated to some extent [46–49] in both pre-clinically and clinically in NRAS codon 61 mutant melanoma, significant toxicities from this regimen have clinically been described [46].